synthetic adeno-associated viral vector-based ASAH1 gene therapy (Gromit Therapeutics/Icahn School of Medicine/Hebrew University of Jerusalem)

N/A

Report date: 2025/01/26 15:53:58

Base Information

Drug Namesynthetic adeno-associated viral vector-based ASAH1 gene therapy (Gromit Therapeutics/Icahn School of Medicine/Hebrew University of Jerusalem)
Drug Alias NameASAH1 gene therapy (Gromit Therapeutics/Icahn School of Medicine/Hebrew University of Jerusalem)Anc80L65 vector-based ASAH1 gene therapy (Gromit Therapeutics/Icahn School of Medicine/Hebrew University of Jerusalem)
ClassificationBiologics
Mechanisms of ActionAcid ceramidase stimulants
TargetsAcid ceramidase
Therapy Area/IndicationsHypertension, Pulmonary
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesIsrael
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
China Registration ClassN/A

Develop Information

Inactive CompaniesN/A
Active IndicationsHypertension, Pulmonary
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A